{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:31:12Z","timestamp":1788877872464,"version":"build-2803163510"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>This mini-review provides an update on the challenges and controversies surrounding levothyroxine therapy in thyroidectomized patients, following an extensive review on dosing strategies and available formulations. Despite efforts to establish an ideal dosage adjustment method, achieving optimal thyroid hormone replacement remains complex due to interindividual variations in the hypothalamic\u2013pituitary\u2013thyroid axis and the pharmacokinetic and pharmacodynamic limitations of exogenous levothyroxine. Additionally, this review highlights the importance of evaluating the risk-benefit ratio of levothyroxine therapy, particularly in the setting of TSH suppression, focusing on its effects on quality of life, bone metabolism, and cardiac rhythm. Levothyroxine-induced subclinical hyperthyroidism may contribute to an increased risk of atrial fibrillation and alterations in bone mineral density, with implications that remain a subject of debate. Given the incomplete replication of endogenous thyroid hormone action by levothyroxine monotherapy, a tailored therapeutic approach is crucial. Despite ongoing research, the optimal management of thyroidectomized patients continues to be an open issue<\/jats:p>","DOI":"10.3389\/fendo.2025.1582734","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:10:46Z","timestamp":1748232646000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Levothyroxine therapy in thyroidectomized patients: ongoing challenges and controversies"],"prefix":"10.3389","volume":"16","author":[{"given":"Leonardo","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinunzia","family":"Paternoster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Cammarata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohail","family":"Bakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Miccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0125","article-title":"Patient-tailored levothyroxine dosage with pharmacokinetic\/pharmacodynamic modeling: A novel approach after total thyroidectomy","volume":"31","author":"Brun","year":"2021","journal-title":"Thyroid"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2021.03.016","article-title":"Comparison of dosing schemes for thyroid hormone replacement therapy after thyroidectomy","volume":"264","author":"Valenzuela","year":"2021","journal-title":"J Surg Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.626268","article-title":"Levothyroxine therapy in thyrodectomized patients","volume":"11","author":"Miccoli","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000356507","article-title":"2013 ETA guideline: management of subclinical hypothyroidism","volume":"2","author":"Pearce","year":"2013","journal-title":"Eur Thyroid J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/jso.v126.4","article-title":"Quality of life following lobectomy versus total thyroidectomy is significantly related to hypothyroidism","volume":"126","author":"Yaniv","year":"2022","journal-title":"J Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261160","article-title":"Prevalence and factors associated with chronic use of levothyroxine: A cohort study","volume":"16","author":"Janett-Pellegri","year":"2021","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0485","article-title":"Risk of over- and under- treatment with levothyroxine in primary care in Copenhagen, Denmark","volume":"185","author":"la Cour","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01390-7","article-title":"Profiling retrospective thyroid function data in complete thyroidectomy patients to investigate the HPT axis set point (PREDICT-IT)","volume":"44","author":"Li","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2024.0045","article-title":"Towards personalized TSH reference ranges: A genetic and population-based approach in three independent cohorts","volume":"34","author":"Ku\u015b","year":"2024","journal-title":"Thyroid"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.04.097","article-title":"The optimal dosing scheme for levothyroxine after thyroidectomy: A comprehensive comparison and evaluation","volume":"165","author":"Zaborek","year":"2019","journal-title":"Surgery"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022552","article-title":"Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients","volume":"6","author":"Gullo","year":"2011","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13044-022-00127-3","article-title":"Proportion of serum thyroid hormone concentrations within the reference ranges in athyreotic patients on levothyroxine monotherapy: a retrospective study","volume":"15","author":"Ito","year":"2022","journal-title":"Thyroid Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0426","article-title":"Biochemical markers reflecting thyroid function in athyreotic patients on levothyroxine monotherapy","volume":"27","author":"Ito","year":"2017","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ19-0094","article-title":"Thyroid function related symptoms during levothyroxine monotherapy in athyreotic patients","volume":"66","author":"Ito","year":"2019","journal-title":"Endocr J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac725","article-title":"Serum thyrotropin and triiodothyronine levels in levothyroxine-treated patients","volume":"108","author":"Ettleson","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.7.769","article-title":"Triiodothyronine levels in athyreotic individuals during levothyroxine therapy","volume":"299","author":"Jonklaas","year":"2008","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI77588","article-title":"Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine","volume":"125","author":"Werneck de Castro","year":"2015","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13237465","article-title":"Metabolic consequences of thyroidectomy and patient-centered management","volume":"13","author":"Wang","year":"2024","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-022-03110-y","article-title":"Levothyroxine-induced serum free thyroxine response following radioactive iodine administration in patients thyroidectomized for differentiated thyroid cancer: A randomized controlled trial","volume":"77","author":"Marina","year":"2022","journal-title":"Endocrine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12020-019-02049-x","article-title":"Novel thyroxine formulations: a further step toward precision medicine","volume":"66","author":"Virili","year":"2019","journal-title":"Endocrine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.633587","article-title":"The stability of TSH, and thyroid hormones, in patients treated with tablet, or liquid levo-thyroxine","volume":"12","author":"Antonelli","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10225233","article-title":"Improvements in quality of life and thyroid parameters in hypothyroid patients on ethanol-free formula of liquid levothyroxine therapy in comparison to tablet LT4 form: an observational study","volume":"10","author":"Bornikowska","year":"2021","journal-title":"J Clin Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.626371","article-title":"L-T4 therapy in enteric malabsorptive disorders","volume":"12","author":"Fallahi","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1386629","article-title":"Liquid L-T4 therapy in hypothyroid patients with gastric diseases, an observational study","volume":"15","author":"Fallahi","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/lio2.v3.5","article-title":"Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): A prospective study","volume":"3","author":"Fallahi","year":"2018","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/thy.2020.0515","article-title":"New formulations of levothyroxine in the treatment of hypothyroidism: trick or treat","volume":"31","author":"Nagy","year":"2021","journal-title":"Thyroid"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-022-00376-9","article-title":"Seeking optimization of LT4 treatment in patients with differentiated thyroid cancer","volume":"21","author":"Stramazzo","year":"2022","journal-title":"Hormones (Athens)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1210\/endrev\/bnac030","article-title":"Levothyroxine: conventional and novel drug delivery formulations","volume":"44","author":"Liu","year":"2023","journal-title":"Endocr Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154296","article-title":"Long-term adherence to levothyroxine replacement therapy in thyroidectomized patients","volume":"11","author":"Bocale","year":"2022","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1055\/a-1639-1024","article-title":"Effects of chronic suppression or oversuppression of thyroid-stimulating hormone on psychological symptoms and sleep quality in patients with differentiated thyroid cancer","volume":"53","author":"Altunta\u015f","year":"2021","journal-title":"Hormone Metab Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01654.x","article-title":"Psychological well-being in patients on \u201cadequate\u201d doses of l-thyroxine: results of a large, controlled community-based questionnaire study","volume":"57","author":"Saravanan","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01903-6","article-title":"Changes in quality of life after thyroidectomy in subjects with thyroid cancer in relation to the dose of levothyroxine","volume":"46","author":"Monzani","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-1229","article-title":"Recent evidence sets therapeutic targets for levothyroxine-treated patients with primary hypothyroidism based on risk of death","volume":"184","author":"Perros","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa889","article-title":"Effect of initial treatment choice on 2-year quality of life in patients with low-risk papillary thyroid microcarcinoma","volume":"106","author":"Moon","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4174\/astr.2024.106.1.19","article-title":"Effect of thyroid-stimulating hormone suppression on quality of life in thyroid lobectomy patients: interim analysis of a multicenter, randomized controlled trial in low- to intermediate-risk thyroid cancer patients (MASTER study)","volume":"106","author":"Lee","year":"2024","journal-title":"Ann Surg Treat Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.07.013","article-title":"Thyroid function and cognitive decline: A narrative review","volume":"30","author":"Sinha","year":"2024","journal-title":"Endocr Pract"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.87.5.1435","article-title":"The thyroid and the heart","volume":"87","author":"Polikar","year":"1993","journal-title":"Circulation"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.119370","article-title":"Subclinical hyperthyroidism as a risk factor for atrial fibrillation","volume":"142","author":"Auer","year":"2001","journal-title":"Am Heart J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28060420","article-title":"Occurrence of arrhythmias in women with thyroid cancer receiving suppressive doses of levothyroxine","volume":"28","author":"Kazir\u00f3d-Wolski","year":"2021","journal-title":"Curr Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ahj.2020.09.016","article-title":"Levothyroxine dose and risk of atrial fibrillation: A nested case-control study","volume":"232","author":"Gong","year":"2021","journal-title":"Am Heart J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.758043","article-title":"Levothyroxine treatment and the risk of cardiac arrhythmias \u2013 focus on the patient submitted to thyroid surgery","volume":"12","author":"Gluvic","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021190","article-title":"Effect of thyrotropin suppressive therapy on heart rate variability and QT dispersion in patients with differentiated thyroid cancer","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine"},{"key":"B44","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/07435800.2024.2383669","article-title":"Do different TSH suppression levels effect heart rate variability and QT dispersions in patients with differentiated thyroid cancer","volume":"50","author":"\u00c7elik","year":"2025","journal-title":"Endocr Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1177\/0003319721993343","article-title":"The assessment of ventricular arrhythmia indicators based on electrocardiography in patients with differentiated thyroid cancer followed up with levothyroxine suppression","volume":"72","author":"Hepsen","year":"2021","journal-title":"Angiology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2011.09.013","article-title":"Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: A prospective controlled study","volume":"150","author":"Sugitani","year":"2011","journal-title":"Surgery"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1001\/jama.2015.5161","article-title":"Subclinical thyroid dysfunction and fracture risk","volume":"313","author":"Blum","year":"2015","journal-title":"JAMA"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043007","article-title":"Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis","volume":"11","author":"Kwak","year":"2021","journal-title":"BMJ Open"},{"key":"B49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.11005\/jbm.2019.26.1.51","article-title":"Influence of thyroid-stimulating hormone suppression therapy on bone mineral density in patients with differentiated thyroid cancer: A meta-analysis","volume":"26","author":"Yoon","year":"2019","journal-title":"J Bone Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202001_20077","article-title":"TSH-suppressive therapy can reduce bone mineral density in patients with differentiated thyroid carcinoma: a meta-analysis","volume":"24","author":"Wang","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01537-0","article-title":"Trabecular bone score in women with differentiated thyroid cancer on long-term TSH-suppressive therapy","volume":"44","author":"Sousa","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2016.09.005","article-title":"Trabecular bone score: A new DXA-derived measurement for fracture risk assessment","volume":"46","author":"Silva","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1286947","article-title":"Assessment for bone health in patients with differentiated thyroid carcinoma after postoperative thyroid-stimulating hormone suppression therapy: a new fracture risk assessment algorithm","volume":"14","author":"Jia","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1378174","article-title":"Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study","volume":"34","author":"Lin","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0167","article-title":"TSH suppressive therapy and bone","volume":"9","author":"Brancatella","year":"2020","journal-title":"Endocr Connect"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-022-03186-6","article-title":"Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study","volume":"79","author":"Wang","year":"2023","journal-title":"Endocrine"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01933","article-title":"Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma","volume":"153","author":"Heijckmann","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00771-2","article-title":"TSH is a negative regulator of skeletal remodeling","volume":"115","author":"Abe","year":"2003","journal-title":"Cell"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1582734\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:10:47Z","timestamp":1748232647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1582734\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":58,"alternative-id":["10.3389\/fendo.2025.1582734"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1582734","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"article-number":"1582734"}}